Efavirenz vs Indinavir Regimens in HIV (Study 006)

Phase 3, randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients with plasma HIV-1 RNA levels less than 400 copies/mL at 24 weeks. Status: completed.